The Catalyst

USTR Continues the Vital IP Dialogue

Posted by Jay Taylor on February 24, 2015 at 1:35 PM

Understanding how intrinsic intellectual property (IP) is to the United States economy (innovative industries support more than a quarter of all jobs in the U.S.), the Office of the U.S. Trade Representative (USTR) each year releases the Special 301 Report, which details the trade barriers that exist with our trading partners and places certain countries on designated “watch lists.” Since innovation is fundamental to the success of the biopharmaceutical industry in developing the next generation treatments and cures for the world’s patients, PhRMA always seizes upon the opportunity to submit commentary on behalf of our member companies for consideration in the compilation of the final report. In addition to submitting our recommendations, I also testified before the Special 301 Subcommittee today to reiterate several of our concerns about our trading partners’ understanding of adequate IP protections.

Read More

Topics: IP, TPP, 301 Report, USTR

Medicare Monday: Medicare Part D & Adherence Help High Cholesterol Patients Save

Posted by Allyson Funk on February 23, 2015 at 10:00 AM

According to the Centers for Disease Control and Prevention, one in three American adults has high cholesterol. For those struggling with high cholesterol, getting needed prescriptions and adhering to the prescribed treatment regimen is critical. As Peggy, a Georgia widow with high cholesterol noted, Medicare Part D has relieved the stress of having to decide between purchasing vital medicines or food, and as a result, she can now treat her chronic condition consistently. 

Read More

Topics: adherence, CDC, Patient Story, Part D, #MedicareMonday, Cholesterol

India—Seizing the Opportunity

Posted by Bill Chin on February 19, 2015 at 6:00 AM

I am excited to be in India this week to discuss the scientific landscape of pharmaceutical research and development. Everywhere I go I see so much potential for India to become a leader in the discovery and development of innovative medicines. India has a large cadre of well-trained pharmaceutical scientists and has more U.S. FDA-approved pharmaceutical facilities than any other foreign country. This country is ripe for growth in discovering and developing new medicines, not only for the people of India but others around the world.

Read More

Topics: R&D, Drug Development, Clinical Trials, India

PhRMA Foundation Launches New Web Platform

Posted by Eileen Cannon on February 18, 2015 at 12:50 PM

For 50 years, the PhRMA Foundation has supported young scientists in their efforts to pursue careers in research and education that will ultimately lead to improved care and treatment options for patients. With our continued commitment to this goal in mind, I’m excited to announce the launch of the Foundation’s new web platform, www.phrmafoundation.org, which offers new resources on our competitive research grants and fellowships in the most challenging areas of drug discovery.

Read More

Topics: Science, Drug Development, PhRMA Foundation, NIH

Medicare Monday: Managing Diabetes Thanks to Medicare Part D

Posted by Allyson Funk on February 16, 2015 at 10:00 AM

Managing diabetes treatments is a big task. Medicare Part D helps patients access needed medicines, keeps costs low and helps avoid costly hospitalizations and complications.  According to Betty, a mother of five from California, she can afford her diabetes prescriptions thanks to Part D and feels more secure as a result.

Read More

Topics: diabetes, Patient Story, Part D, Medicare, #MedicareMonday

Week in Review: Vaccine Myth Busters Edition

Posted by Christian Clymer on February 13, 2015 at 10:00 AM

The internet provides us with a wealth of information right at our fingertips, but it’s important to be mindful of misinformation, especially as it pertains to your health. With myths and facts swirling about important health topics this week, we cut through the clutter to bring you the facts.

Read More

Topics: Week in Review, Vaccines, health insurance, Avalere Health, exchanges

Health Insurance Exchange Plans Increasingly Putting Needed Medicines Out of Reach

Posted by Allyson Funk on February 11, 2015 at 4:44 PM

Last year, PhRMA was joined by patient groups to highlight an analysis that found a majority of plans in health insurance exchanges required relatively high cost sharing for all medicines in at least one class. The cost burden leaves many patients with no other option, forcing them to make tough choices or go without needed medicines, ultimately having a negative impact on their health.

Read More

Topics: Access, health insurance, Avalere Health, exchanges

PhRMA Salutes Outgoing FDA Commissioner’s Leadership, Looks Forward to Continued Collaboration

Posted by Bill Chin on February 10, 2015 at 11:43 AM

Last week, Food and Drug Administration (FDA) Commissioner Margaret Hamburg announced that she will step down from her post at the end of next month.

Read More

Topics: FDA

Medicare Monday: Congestive Heart Failure Patients Benefit From Taking Advantage of Part D

Posted by Allyson Funk on February 9, 2015 at 4:34 PM

When a Medicare Part D beneficiary adheres to their prescription regimen, both the individual and the broader health care system benefit. The Congressional Budget Office (CBO), for example, now estimates increasing the number of Part D prescriptions filled by just 1 percent reduces program spending on medical services by approximately 0.20 percent. The cost savings are even greater for seniors with certain chronic conditions. Today, we’re looking at congestive heart failure.

Read More

Topics: Patient Story, Part D, CBO, Medicare, #MedicareMonday, congestive heart failure

New Report: Forecasts for Specialty Medicines Have Been Overstated

Posted by Jennifer Bryant on February 9, 2015 at 2:31 PM

According to a new report from actuaries Gabriela Dieguez, Bruce Pyenson and Jennifer Carioto, at Milliman, major pharmacy benefits managers (PBMs) often overestimate future spending on specialty medicines, sometimes by nearly 10 percentage points.

Read More

Topics: tier, Specialty Medicines, Milliman, health care spending, Pharmacy Benefit Managers

Comment on this post

Personalized Updates

Posts by Topic

see more